Hi, your search found this article for you on Trip:

[A controlled clinical study of Pneumorel Retard tablets in the treatment of chronic bronchitis (author's transl)].

La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris, 1979


[A controlled clinical study of Pneumorel Retard tablets in the treatment of chronic bronchitis (author's transl)].
Abstract The authors studied the action of Pneumorel retard tablets in the treatment of chronic bronchitis, comparing 2 groups of 20 patients each, one group was prescribed 1 pneumorel retard tablet in the morning and evening and the other group was treated with a speciality associating proteolytic enzymes and balsamics; the 2 groups also received an antibiotic treatment.
Pneumorel retard showed to be significantly more active on the criteria studied (cough, dyspnea, expectoration, signs of auscultation) and this more often than not from the 10th day of treatment.
Clinical and biological tolerance was perfect concerning the hepatic sphere, gastrointestinal, renal or cardiovascular systems.
The convenience of the use of Pneumorel retard is particularly indicated in the thorough long-term treatment of chronic bronchitis, in preventing episodes of over-infection, worsening the disease.
[Evaluation and symptomatic treatment of surinfectious exacerbations of COPD: preliminary study of antibiotic treatment combined with fenspiride (Pneumorel 80mg) versus placebo].
[A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis].
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm.
Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.